Back to today’s briefing

Story perspectives

FDA Fast Tracks LYT-200 for Acute Myeloid Leukemia

1/9/2025

36 6

Summary

Story summary

PureTech Health celebrates a significant milestone as the FDA grants Fast Track designation to LYT-200, a groundbreaking monoclonal antibody designed to combat acute myeloid leukemia (AML). This innovative treatment, currently in Phase 1/2 trials for AML/MDS and head and neck cancers, promises to accelerate hope for patients facing these serious conditions.

1 of 1

Story summary

PureTech Health celebrates a significant milestone as the FDA grants Fast Track designation to LYT-200, a groundbreaking monoclonal antibody designed to combat acute myeloid leukemia (AML). This innovative treatment, currently in Phase 1/2 trials for AML/MDS and head and neck cancers, promises to accelerate hope for patients facing these serious conditions.